HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂.

Abstract
Norepinephrine transporter (NET) plays important roles in the treatment of various neuropsychiatric disorders, such as depression and attention deficit hyperactivity disorder (ADHD). Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression. Previous positron emission tomography (PET) studies have reported over 80% serotonin transporter occupancy with clinical doses of selective serotonin reuptake inhibitors (SSRIs), but there has been no report of NET occupancy in patients treated with relatively NET-selective antidepressants. In the present study, we used PET and (S,S)-[18¹⁸F]FMeNER-D₂ to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment. Reference data for the calculation of occupancy were derived from age-matched healthy controls. The result showed approximately 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline. The estimated effective dose (ED₅₀) and concentration (EC₅₀) required to induce 50% occupancy was 65.9 mg/d and 79.8 ng/ml, respectively. Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.
AuthorsHarumasa Takano, Ryosuke Arakawa, Tsuyoshi Nogami, Masayuki Suzuki, Tomohisa Nagashima, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Keisuke Takahata, Hitoshi Shimada, Yoshitaka Murakami, Amane Tateno, Makiko Yamada, Hiroshi Ito, Kazunori Kawamura, Ming-Rong Zhang, Hidehiko Takahashi, Motoichiro Kato, Yoshiro Okubo, Tetsuya Suhara
JournalThe international journal of neuropsychopharmacology (Int J Neuropsychopharmacol) Vol. 17 Issue 4 Pg. 553-60 (Apr 2014) ISSN: 1469-5111 [Electronic] England
PMID24345533 (Publication Type: Journal Article)
Chemical References
  • Antidepressive Agents, Tricyclic
  • Fluorine Radioisotopes
  • Norepinephrine Plasma Membrane Transport Proteins
  • Nortriptyline
Topics
  • Adult
  • Antidepressive Agents, Tricyclic (administration & dosage, blood, pharmacokinetics)
  • Depressive Disorder, Major (drug therapy)
  • Dose-Response Relationship, Drug
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Norepinephrine Plasma Membrane Transport Proteins (metabolism)
  • Nortriptyline (administration & dosage, blood, pharmacokinetics)
  • Positron-Emission Tomography
  • Protein Binding
  • Thalamus (diagnostic imaging, drug effects, metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: